34 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Selective inhibitors of protein methyltransferases.
Icahn School of Medicine At Mount Sinai
Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.
University of North Carolina At Chapel Hill
Analogues of the Natural Product Sinefungin as Inhibitors of EHMT1 and EHMT2.
University of Copenhagen
Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells.
Sapienza University of Rome
Discovery and development of potent and selective inhibitors of histone methyltransferase g9a.
Abbvie
Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors.
University of North Carolina At Chapel Hill
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
University of North Carolina At Chapel Hill
Chemical probes for histone-modifying enzymes.
Johns Hopkins University School of Medicine
Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines.
University of North Carolina At Chapel Hill
Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a.
University of North Carolina
NSD3: Advances in cancer therapeutic potential and inhibitors research.
Peking University
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2).
University of Texas Medical Branch (UTMB)
Structure-Based Discovery of Inhibitors of the SARS-CoV-2 Nsp14 N7-Methyltransferase.
University of California San Francisco
Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP.
Sun Yat-Sen University
Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2.
Sun Yat-Sen University
Discovery of cysteine-targeting covalent histone methyltransferase inhibitors.
Nanjing Medical University
Discovery of Novel Substrate-Competitive Lysine Methyltransferase G9a Inhibitors as Anticancer Agents.
Kyorin Pharmaceutical Co.
Quinazoline-based hydroxamic acid derivatives as dual histone methylation and deacetylation inhibitors for potential anticancer agents.
Tsinghua University
Fascinating Transformation of SAM-Competitive Protein Methyltransferase Inhibitors from Nucleoside Analogues to Non-Nucleoside Analogues.
Csir-Indian Institute of Chemical Biology
Discovery of the First-in-Class G9a/GLP Covalent Inhibitors.
Icahn School of Medicine At Mount Sinai
Identification and in vitro characterization of a new series of potent and highly selective G9a inhibitors as novel anti-fibroadipogenic agents.
Promidis
Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines.
Daiichi Sankyo
Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.
The University of Texas M.D. Anderson Cancer Center
Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase.
Icahn School of Medicine At Mount Sinai
Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.
Wuxi Apptec (Tianjin) Co.
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
Radboud University
Methyllysine binding domains: Structural insight and small molecule probe development.
University of Connecticut
Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
Universidad De Oviedo-Principado De Asturias
Structure-activity relationship studies of G9a-like protein (GLP) inhibitors.
Icahn School of Medicine At Mount Sinai